Key Highlights

  • Opus Genetics (NASDAQ:IRD) held USD 88.8 million of cash at June 30, 2026, up from USD 45.1 million at year end 2025, and expects to fund operations into 2029 excluding Warrant proceeds and milestones.
  • Shares outstanding rose to 82,647,946 from 69,894,507 at year end, an increase of about 18%, simple arithmetic on two reported figures, while warrant liabilities stood at USD 62.1 million.
  • The lead gene therapy OPGx-LCA5 has a registrational Phase 3 trial of eight participants, with dosing expected in the fourth quarter of 2026 and topline data by year end 2027.
  • Partner Viatris faces an FDA date of October 17, 2026 for MR-141 in presbyopia, and Opus Genetics (NASDAQ:IRD) is party to a global licensing agreement whose terms were not disclosed.

The Q2 Snapshot

Opus Genetics reported second quarter 2026 results on August 6, 2026. Cash and equivalents were USD 88.8 million, up from USD 45.1 million at December 31, 2025. License and collaboration Revenue fell to USD 0.8 million from USD 2.9 million, mostly reimbursement of research services under the Viatris collaboration. Research and Development expense rose to USD 11.2 million from USD 6.0 million on higher Manufacturing and clinical costs, general and administrative expense was USD 6.0 million, and the net loss was USD 8.1 million versus USD 7.4 million. Long-term Debt was USD 34.9 million. The company expects its cash to fund operations into 2029, including potential funding under the Oberland note purchase agreement.

Pipeline and the Partner Catalyst

Opus Genetics (NASDAQ:IRD) is advancing five gene therapy programs for inherited retinal diseases. The lead, OPGx-LCA5, has FDA alignment on a registrational Phase 3 trial of eight participants with a six-month run-in, enrollment complete and dosing expected in the fourth quarter of 2026. The company said OPGx-BEST1 three-month data were due in the second week of September 2026, but the result was not verified here. Separately, partner Viatris has an FDA goal date of October 17, 2026 for MR-141 in presbyopia. Opus is party to the licensing agreement, but the documents reviewed did not disclose what Opus would receive, so any benefit is unquantified and should not be assumed.

Dilution and Risk

The Balance Sheet shows the cost of funding. Shares outstanding grew by about 12.75 million in six months, or about 18%, and warrants are carried at fair value, producing a USD 44.2 million loss in the first half. A rising share price raises the value of warrants and the reported loss. The release also showed a diluted loss per share that looked inconsistent with other figures, so per-share numbers are omitted. Gene therapy trials can fail, and the Viatris decision may be delayed or negative. Watch the October 17 outcome, dosing news and any financing. A reported year to date gain near 116% is unverified. This is not Investment advice.

Where Things Stand

Opus Genetics (NASDAQ:IRD) stands to gain indirectly if Viatris wins approval for MR-141 on October 17, 2026, but the size of that gain is unknown because the licensing terms were not disclosed in the documents reviewed. The company's own value rests on its gene therapy pipeline and a cash balance of USD 88.8 million, financed in part by dilution. The balance of evidence is mixed. The next catalysts are the FDA action date and fourth quarter dosing of OPGx-LCA5.